相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).
Sumanta K. Pal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
M. Tazdait et al.
EUROPEAN JOURNAL OF CANCER (2018)
CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-Results of a phase III noninferiority trial.
Arnaud Mejean et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Check point inhibitors a new era in renal cell carcinoma treatment
Mohamed Alsharedi et al.
MEDICAL ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Vadim S. Koshkin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Recommendations for the Management of Rare Kidney Cancers
Rachel H. Giles et al.
EUROPEAN UROLOGY (2017)
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier et al.
EUROPEAN UROLOGY (2017)
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier et al.
EUROPEAN UROLOGY (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
James Xunhai Xu et al.
ONCOLOGIST (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.
Karina Kulangara et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
B. Lee et al.
ANNALS OF ONCOLOGY (2016)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis
O. Abdel-Rahman et al.
CLINICAL ONCOLOGY (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2016)
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella et al.
LANCET ONCOLOGY (2016)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial
Saby George et al.
JAMA ONCOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I. Rini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2015)
High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).
Sandra Aung et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Richard W. Joseph et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2015)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L. Kaufman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic value of histologic subtypes in renal cell carcinoma:: A multicenter experience
JJ Patard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
